134 episodes

The Syneos Health Podcast Series dissects some of the most complex issues biopharma leaders are facing today. Our clinical and commercial experts provide time-tested solutions, as well as perspectives on the news of the day. Hosted by Jeff Stewart, a long-time industry consultant who has advised biopharma leaders on licensing, mergers and acquisitions, pricing and market access, commercialization and go-to-market strategies, each episode explores the challenges and considerations involved with bringing biopharmaceuticals to the market.

The Syneos Health Podcast Jeffrey Stewart

    • Business
    • 4.9 • 42 Ratings

The Syneos Health Podcast Series dissects some of the most complex issues biopharma leaders are facing today. Our clinical and commercial experts provide time-tested solutions, as well as perspectives on the news of the day. Hosted by Jeff Stewart, a long-time industry consultant who has advised biopharma leaders on licensing, mergers and acquisitions, pricing and market access, commercialization and go-to-market strategies, each episode explores the challenges and considerations involved with bringing biopharmaceuticals to the market.

    Ophthalmology Clinical Trials: Low Vision and AMD Awareness Month

    Ophthalmology Clinical Trials: Low Vision and AMD Awareness Month

    Age-related vision loss is a rising concern for our growing aging population. According to the most recent data published by the CDC, nearly 20 million Americans aged 40+ have been diagnosed with some form of age-related macular degeneration (AMD). By the age of 75, roughly 1 in 3 people living in the United States will have some form of AMD, and about 1 in 4 of those will have a vision-threatening, late-stage form of AMD. These statistics underscore the need for heightened public awareness and increased accessibility to innovative treatments.
    February is Low Vision and Age-Related Macular Degeneration (AMD) Awareness Month. In this episode, Laszlo Bekesi, MD, Vice President of Strategy and Innovation, and Jonathan Angelastro, Executive Director of Project Delivery at Syneos Health provide valuable insights into the evolving field of ophthalmology and the efforts to address the growing burden of age-related vision impairment—with a  focus on understanding both wet and dry AMD types, the complexities of AMD, its impact on vision and the urgency for early detection and treatment. They also discuss the current landscape of research and development in the space and highlight the opportunities for—and inherent operational challenges of—conducting clinical trials in ophthalmology.


    The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.

    If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health.

    Like what you’re hearing? Be sure to rate and review us!

    We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

    • 25 min
    FDA Rules for Radio & TV Advertising

    FDA Rules for Radio & TV Advertising

    The FDA has finalized a rule that addresses how drug ads must be presented in TV and radio commercials. The rule, proposed in 2010 and now effective from May of this year, aims to provide clarity and guidelines for pharmaceutical companies in presenting side effects and contraindications in a balanced manner. But it’s still a 27-page document.

    Here, we’ll boil it down for you.

    Matthew Snodgrass, head of US Digital and Social Strategy at Syneos Health, sheds light on the 13-year journey from proposal to finalization, exploring key aspects of the rule, restrictions on distracting visuals during side effect discussions, and the use of quantitative terminology to convey information more precisely. The conversation delves into the challenges faced by regulatory teams in interpreting and implementing these rules and highlights the importance of understanding and following FDA guidelines in pharmaceutical advertising.

    For a more detailed exploration of the FDA rule, check out our highlighted version of the full document in a downloadable PDF format. 



    The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.

    If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health.

    Like what you’re hearing? Be sure to rate and review us!

    We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

    • 19 min
    2024 Health Trends: Managing the Healthcare Revolution

    2024 Health Trends: Managing the Healthcare Revolution

    Nervousness and uncertainty surround the question of what Artificial Intelligence (AI) may mean for the future of work. How can we deploy AI transformation—thoughtfully—across an organization and help workforces see what the new models will signify and require of us?

    In the first episode in this series related to our 2024 Health Trends, host Jeff Stewart is joined by Celeste Mosby, Senior Vice President and General Manager of Syneos Health Learning Solutions, to discuss the challenges of managing this healthcare revolution, especially in terms of training and adapting to the rapidly evolving landscape.

    The conversation highlights the shift in the industry over the past five years, where technology, data and AI are now shaping the healthcare landscape—requiring professionals to keep up with the dynamic changes—and explores the impact of AI on human-to-human interactions, workforce training and the importance of thought leaders staying ahead of evolving trends.

    For additional insights into Revolution Management, Learning and Change in the New World of Work—as well as the year(s) of reinvention ahead for the life sciences sector—download our 2024 Health Trends report.


    The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.

    If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health.

    Like what you’re hearing? Be sure to rate and review us!

    We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

    • 16 min
    World Mental Health Day: The State of Mental Health Clinical Development

    World Mental Health Day: The State of Mental Health Clinical Development

    October is National Depression and Mental Health Screening Month, with October 10th specifically recognized as World Mental Health Day. A recent study co-led by Harvard Medical School and the University of Queensland established that one out of every two people in the world will develop a mental health disorder in their lifetime. This staggering number underscores the critical need to reduce the stigma of mental health, and to make sure that people who are suffering understand the diverse help and treatment options that are available to them.
    Dr. Alexandria Wise, Global Head of Therapeutic Strategy and Innovation and Andy Moniz, VP, Therapeutic Strategy and Innovation at Syneos Health, join the podcast to help raise mental health awareness, discussing the evolution in mental health treatment over the past 30 years and where it stands today; the challenges of mental healthcare access for certain patient groups and what is being done to ease this; and the unique aspects of psychedelics in mental health clinical trials and their potential for promising results.

    For more content on neuroscience topics, check out these insights:
    Understanding the Role of the Placebo Response in Clinical Trials
    Digital Flexibility and the Digital Divide: Meeting Patients Where They're At With Mental Health Services
    WEBINAR | Psychedelics 3.0: Drug Development Challenges and Opportunities in a Rapidly Evolving Field
    The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.

    If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health.

    Like what you’re hearing? Be sure to rate and review us!

    We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

    • 24 min
    Radiosensitizers in Head and Neck Cancer

    Radiosensitizers in Head and Neck Cancer

    Radiosensitizers have emerged as potential game-changers in head and neck cancer therapy. A diverse group of compounds, radiosensitizers enhance radiation therapy's impact on tumor cells. Ongoing research seeks radiosensitizers that augment radiotherapy's efficacy without increasing toxicity, offering exciting prospects for the APAC region and beyond.


    Our new APAC Edition host Lance Eminger, Executive Director of Business Development is joined by Dr. Juan Manuel Carrera, Senior Medical Director at Syneos Health to discuss what radiosensitizers are and how they work—highlighting the potential of new radiosensitizers to redefine cancer treatment, fostering better results with fewer side effects.
    The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.

    If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health.

    Like what you’re hearing? Be sure to rate and review us!

    We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

    • 14 min
    Market Access for Weight Loss Drugs

    Market Access for Weight Loss Drugs

    One of the biggest trends making headlines and impacting the healthcare industry to date is the rising popularity of GLP-1 drugs. Initially developed for diabetes management, these products have recently gained traction for weight loss indications. But with promising efficacy and growing popularity, is the healthcare industry truly prepared for the challenges posed by these drugs becoming such a hot commodity in the market?
    Tom Albers, Vice President of Strategy at Syneos Health company Spherico, joins the podcast to discuss his insights on the future of weight loss drugs – payer challenges, the transformative potential of these drugs, and the need for smart investments in data and evidence.

    For more content on value and access, check out these insights:
     MM+M Podcast | Gaining Access and Delivering Pull-Through in IDNs and Key Accounts
    Syneos Health Podcast: The Inflation Reduction Act
    Building a Market Access Case for Real World Evidence in Oncology


    The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.

    If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health.

    Like what you’re hearing? Be sure to rate and review us!

    We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

    • 21 min

Customer Reviews

4.9 out of 5
42 Ratings

42 Ratings

Blue dome ,

Insightful life sciences podcast

As an executive in the pharma space, I look forward to each new episode

bea s v ,

Insightful podcast

Syneos podcast has become a consistent and high quality source of information and trends to me about the pharma industry. Jeff brings pertinent questions to get insightful answers and the topics are more and more diverse. Really well done.

Top Podcasts In Business

Udemy
NerdWallet Personal Finance
Ramsey Network
Money News Network
Shawn D. Nelson
DOAC

You Might Also Like

STAT
The New York Times
Hidden Brain, Shankar Vedantam
NPR
NPR
Harvard Business Review